Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092915 | 0.82 | MAOB (0.38) | — | |
| SCHEMBL2092917 | 0.82 | MAOB (0.38) | — | |
| SCHEMBL22418044 | 0.81 | PTP4A3 (0.43) | PTP4A3TRPV4NFE2L2ARP4HB | |
| SCHEMBL2658682 | 0.81 | PTP4A3 (0.46) | PTP4A3TRPV4ARP4HBGRM4 | |
| SCHEMBL21676227 | 0.79 | PTP4A3 (0.45) | PTP4A3TRPV4NFE2L2ARP4HB | |
| SCHEMBL5971177 | 0.77 | ALDH1A1 (0.47) | PTP4A3TRPV4NFE2L2ARP4HB | |
| SCHEMBL2992295 | 0.77 | PTP4A3 (0.41) | PTP4A3TRPV4NFE2L2ARPGR | |
| SCHEMBL2992292 | 0.77 | PTP4A3 (0.41) | PTP4A3TRPV4NFE2L2ARPGR | |
| SCHEMBL16957506 | 0.77 | PTP4A3 (0.46) | PTP4A3TRPV4ARP4HBGRM4 | |
| SCHEMBL48778 | 0.77 | PTP4A3 (0.49) | PTP4A3TRPV4ARP4HBGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | claimed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | claimed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | PTP4A3 786/4885TRPV4 2990/4885NFE2L2 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.